Literature DB >> 10844488

The management of oral lichen planus.

J F Setterfield1, M M Black, S J Challacombe.   

Abstract

Oral lichen planus is a relatively common inflammatory disease affecting between 0.5% and 2.2% of the population in epidemiological studies. In contrast with cutaneous lichen planus (LP), in which the clinical course is often mild and resolves within 2 years, mucosal LP tends to follow a more chronic course often punctuated by acute exacerbations. Furthermore, although distinct clinical subtypes such as reticular, atrophic, hypertrophic and erosive forms are well recognized, more than one clinical phenotype may be seen at a time. The rare association with oral neoplasia should always be considered and high-risk patients must be kept under close observation. Thus the management of this disorder will vary widely both between patients, and for individual patients, with fluctuations in disease activity. Here we discuss the therapeutic options available and review the evidence for their use.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10844488     DOI: 10.1046/j.1365-2230.2000.00607.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  8 in total

1.  Role of Cathepsin B as a Marker of Malignant Transformation in Oral Lichen Planus: An Immunohistochemical Study.

Authors:  Krishnanand Prakash Satelur; Shiny Bopaiah; Radhika Manoj Bavle; Prashant Ramachandra
Journal:  J Clin Diagn Res       Date:  2017-08-01

2.  Anti-inflammatory effects of astaxanthin in the human gingival keratinocyte line NDUSD-1.

Authors:  Masashiro Miyachi; Tomonori Matsuno; Kazunari Asano; Izumi Mataga
Journal:  J Clin Biochem Nutr       Date:  2015-01-29       Impact factor: 3.114

3.  Photodynamic therapy in oral lichen planus: A prospective case-controlled pilot study.

Authors:  Raluca Cosgarea; Robert Pollmann; Jusra Sharif; Thomas Schmidt; Ronja Stein; Aura Bodea; Thorsten Auschill; Anton Sculean; Rüdiger Eming; Brandon Greene; Michael Hertl; Nicole Arweiler
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

4.  Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal Diseases.

Authors:  Raul Diaz-Salmeron; Balthazar Toussaint; Nicolas Huang; Etienne Bourgeois Ducournau; Gabriel Alviset; Sophie Goulay Dufaÿ; Hervé Hillaireau; Amélie Dufaÿ Wojcicki; Vincent Boudy
Journal:  Pharmaceutics       Date:  2021-01-18       Impact factor: 6.321

5.  Estimation and comparison of levels of salivary nitric oxide in patients with oral lichen planus and controls.

Authors:  Sapna Panjwani; Anjana Bagewadi; Vaishali Keluskar; Rohit Malik; Shalu Rai; Deepankar Misra
Journal:  Int J Prev Med       Date:  2013-06

6.  Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial.

Authors:  Fariba Iraji; Ali Asilian; Ahmad Saeidi; Amir Hossein Siadat; Ali Reza Saeidi; Akbar Hassanzadeh
Journal:  Adv Biomed Res       Date:  2013-07-30

7.  A randomized triple-blind clinical trial to compare the effectiveness of topical triamcinolone acetonate (0.1%), clobetasol propionate (0.05%), and tacrolimus orabase (0.03%) in the management of oral lichen planus.

Authors:  Shivakumar Sivaraman; Krishnamoorthy Santham; Aruldoss Nelson; Bijaykumar Laliytha; Pandian Azhalvel; John Hearty Deepak
Journal:  J Pharm Bioallied Sci       Date:  2016-10

Review 8.  Oral lichen planus: a novel staging and algorithmic approach and all that is essential to know.

Authors:  Eran Shavit; Klieb Hagen; Neil Shear
Journal:  F1000Res       Date:  2020-03-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.